Michael Crackower

Michael Crackower

Company: Ventus Therapeutics

Job title: Chief Scientific Officer


Discovery, Characterization, & Advancement, of Novel Chemotypes of Potent & Selective Brain Penetrant & Peripherally Restricted NLRP3 Inhibitors 10:00 am

Hear about the first study of Selnoflast in participants with early idiopathic PD; characterization of a new compound targeting NLRP3 inflammasome and innovative Ph1b design to test safety, pharmacokinetics and pharmacodynamicsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.